Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | PAM | P19021 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16944249 | 0.91 | DGKA (0.50) | DGKATSHRADRA2AADRA1ADNM1 | |
| SCHEMBL8334997 | 0.90 | DGKA (0.59) | DGKATSHRDNM1MAPTPAM | |
| SCHEMBL26001650 | 0.90 | DGKA (0.44) | DGKATSHRADRA2AADRA1ADNM1 | |
| SCHEMBL756972 | 0.88 | DGKA (0.68) | DGKATSHRDNM1MAPTPAM | |
| SCHEMBL8557522 | 0.86 | DGKA (0.71) | DGKATSHRDNM1MAPTPAM | |
| SCHEMBL9446486 | 0.86 | DGKA (0.60) | DGKATSHRDNM1MAPTPAM | |
| SCHEMBL11079332 | 0.86 | DGKA (0.71) | DGKATSHRDNM1MAPTPAM | |
| SCHEMBL26001723 | 0.86 | DGKA (0.41) | DGKAADRA2AADRA1ADNM1MAPT | |
| SCHEMBL26001663 | 0.86 | DGKA (0.50) | DGKATSHRDNM1MAPTPAM | |
| SCHEMBL26001720 | 0.86 | DGKA (0.41) | DGKAADRA2AADRA1ADNM1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831182-A1 | PREPARATION OF ROSUVASTATIN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-09-12 | — | — | EP | disclosed |
| US-20070167625-A1 | Preparation of rosuvastatin | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-07-19 | — | — | US | disclosed |
| WO-2007041666-A1 | PREPARATION OF ROSUVASTATIN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-04-12 | — | — | WO | disclosed |
| US-20070037979-A1 | Preparation of rosuvastatin | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2007-02-15 | — | — | US | disclosed |
| EP-1737829-A2 | PREPARATION OF ROSUVASTATIN | Teva Pharmaceutical Industries Ltd (IL) | 2007-01-03 | — | — | EP | disclosed |
| WO-2006091771-A2 | PREPARATION OF ROSUVASTATIN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167625-A1 | Preparation of rosuvastatin | HMGCR, PCSK9, PCSK7 | DGKA 1402/4885TSHR 4494/4885ADRA2A 1835/4885 |
| US-20070037979-A1 | Preparation of rosuvastatin | HMGCR, PCSK9, PCSK7 | DGKA 1402/4885TSHR 4494/4885ADRA2A 1835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.